Vinorelbine
Vinorelbine (vinorelbine) is a small molecule pharmaceutical. Vinorelbine was first approved as Navelbine on 1994-12-23. It is used to treat breast neoplasms, hodgkin disease, non-small-cell lung carcinoma, and ovarian neoplasms in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Vinorelbine (discontinued: Navelbine, Vinorelbine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vinorelbine tartrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NAVELBINE | Laboratoires Pierre Fabre | N-020388 DISCN | 1994-12-23 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| vinorelbine | ANDA | 2024-08-16 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9390 | Injection, vinorelbine tartrate, 10 mg |
Clinical
Clinical Trials
577 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 6 | 1 | — | 3 | 11 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 5 | 1 | — | 2 | 8 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | — | C34.90 | — | 3 | — | — | 2 | 5 |
| Animal mammary neoplasms | D015674 | — | — | — | 1 | — | — | — | 1 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | 1 | — | — | — | 1 |
| Head and neck neoplasms | D006258 | — | — | 1 | 1 | — | — | — | 1 |
| Uterine cervical neoplasms | D002583 | — | — | 1 | 1 | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | — | — | — | 1 |
| Malignant mesothelioma | D000086002 | — | — | — | 1 | — | — | — | 1 |
| Mesothelioma | D008654 | — | C45 | — | 1 | — | — | — | 1 |
| Glioma | D005910 | EFO_0000520 | — | — | 1 | — | — | — | 1 |
| Chemoradiotherapy | D059248 | — | — | — | 1 | — | — | — | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vinorelbine |
| INN | vinorelbine |
| Description | Vinorelbine is a vinca alkaloid with a norvinblastine skeleton. It has a role as an antineoplastic agent and a photosensitizing agent. It is a vinca alkaloid, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a methyl ester, an acetate ester and a ring assembly. |
| Classification | Small molecule |
| Drug class | vinca alkaloids |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2 |
Identifiers
| PDB | — |
| CAS-ID | 71486-22-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL553025 |
| ChEBI ID | 480999 |
| PubChem CID | 5311497 |
| DrugBank | DB00361 |
| UNII ID | Q6C979R91Y (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 17,873 documents
View more details
Safety
Black-box Warning
Black-box warning for: Vinorelbine
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
10,858 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use